BAZEDOXIFENE for menopause

Hypothesized mechanism

BAZEDOXIFENE modulates estrogen receptor 2 (ESR2) signaling, compensating for declining estrogen activity associated with menopause.

This is the model’s proposed mechanism from the sources on file, not a demonstrated causal pathway. How well the published record supports it is reflected in the rigor and plausibility dimensions of the score, and traced to the verbatim sources at the foot of the page.

Source evidence · what the pipeline ingested

These are the sources the pipeline ingested to detect and score this signal, the published literature the model actually read, each tagged by study type. Where the model combined findings the claim is marked as a synthesis (S), and where the literature disagrees the contradiction is shown (!).

Every source below belongs to this signal’s evidence arm, Pathway insights. Whel reads each drug-condition pair through four such arms, each held to its own inclusion bar; a signal is surfaced through one of them.

• 1Per Open Targets (retrieved 2026-06-16), BAZEDOXIFENE (a Small molecule) is a clinical candidate for menopause (maximum clinical stage PHASE_3); its mechanism of action is Estrogen receptor modulator on target estrogen receptor 2. Open Targets · mechanistic ↗
• 2In FDA AEMS (the FDA Adverse Event Reporting System, formerly FAERS; retrieved 2026-06-16), 61 report(s) of HOT FLUSH were recorded for BAZEDOXIFENE among female patients (of 779 female reports for BAZEDOXIFENE in the analysed sample). This is a raw adverse-event report count, not a disproportionality statistic or evidence of causation, and is subject to reporting bias and confounding. Read two ways: as a safety consideration, and — because it suggests BAZEDOXIFENE acts on a system relevant to menopause — as a mechanistic lead for further investigation, not evidence of benefit. AEMS · adverse-event report ↗
• 3In FDA AEMS (the FDA Adverse Event Reporting System, formerly FAERS; retrieved 2026-06-16), 28 report(s) of INSOMNIA were recorded for BAZEDOXIFENE among female patients (of 779 female reports for BAZEDOXIFENE in the analysed sample). This is a raw adverse-event report count, not a disproportionality statistic or evidence of causation, and is subject to reporting bias and confounding. Read two ways: as a safety consideration, and — because it suggests BAZEDOXIFENE acts on a system relevant to menopause — as a mechanistic lead for further investigation, not evidence of benefit. AEMS · adverse-event report ↗
• 4In FDA AEMS (the FDA Adverse Event Reporting System, formerly FAERS; retrieved 2026-06-16), 9 report(s) of HYPERHIDROSIS were recorded for BAZEDOXIFENE among female patients (of 779 female reports for BAZEDOXIFENE in the analysed sample). This is a raw adverse-event report count, not a disproportionality statistic or evidence of causation, and is subject to reporting bias and confounding. Read two ways: as a safety consideration, and — because it suggests BAZEDOXIFENE acts on a system relevant to menopause — as a mechanistic lead for further investigation, not evidence of benefit. AEMS · adverse-event report ↗

These are the verbatim sources the pipeline surfaced and read; they may not be the full published record for a pair, and the score reflects the strength and agreement of the evidence rather than its volume. The strength of these source types is what the rigor dimension of the score reads off. MATRIX, sex-specific pharmacokinetics, and cycle phase are separate layers the pipeline does not ingest, external cross-references reported beside the score, and they link to their own sources in their sections above.